Characterization of apoptosis induced by marine natural products in non small cell lung cancer A549 cells

被引:45
作者
Catassi, A.
Cesario, A.
Arzani, D.
Menichini, P.
Alama, A.
Bruzzo, C.
Imperatori, A.
Rotolo, N.
Granone, P.
Russo, P.
机构
[1] Natl Canc Res Inst, DOMI, I-16132 Genoa, Italy
[2] Univ Insubria, Ctr Thorac Surg, Varese, Italy
[3] Univ Cattolica Sacro Cuore, Dept Surg Sci, Div Gen Thorac Surg, Rome, Italy
[4] IRCCS, Clin Resp & Pathol Translat Lab, Rome, Italy
[5] Univ Cattolica Sacro Cuore, Div Hyg, Rome, Italy
[6] Natl Canc Res Inst, Dept Translat Oncol, Mol Mutagenesis Unit, Genoa, Italy
关键词
marine agents; apoptosis; BAD; c-myc; GADD45; non small cell lung cancer;
D O I
10.1007/s00018-006-6264-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effects of different marine derived agents were studied in A549 cell growth. These drugs induced cell cycle arrest at the G(2)-M phase associated with the up-regulation of GADD45 alpha-gamma and down-regulation of c-Myc. In treated cells, GADD45 alpha-gamma and c-Myc were up- and down-regulated, respectively. A cascade of events leading to apoptotic mitochondrial 'intrinsic' pathway was observed in treated cells: (1) dephosphorylation of BAD serine(136); (2) BAD dissociation from 14-3-3 followed by its association with BCL-XL; (3) cytochrome c release; (4) caspase-3 activation, and (5) cleavage of vimentin. Caspase(s) inhibitor prevented the formation of cleavage products and, in turn, apoptosis was inhibited through a p53-independent mechanism. Moreover, these compounds did not activate NF-kappa B. Our findings may offer new insights into the mechanisms of action of these agents in A549 cells. The better understanding of their effects might be important to fully exploit the potential of these new drugs.
引用
收藏
页码:2377 / 2386
页数:10
相关论文
共 52 条
[31]   14-3-3 inhibits bad-induced cell death through interaction with serine-136 [J].
Masters, SC ;
Yang, HZ ;
Datta, SR ;
Greenberg, ME ;
Fu, H .
MOLECULAR PHARMACOLOGY, 2001, 60 (06) :1325-1331
[32]   Marine pharmacology in 2001-2: antitumour and cytotoxic compounds [J].
Mayer, AMS ;
Gustafson, KR .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (18) :2676-2704
[33]   Mechanism targeted discovery of antitumor marine natural products [J].
Nagle, DG ;
Zhou, YD ;
Mora, FD ;
Mohammed, KA ;
Kim, YP .
CURRENT MEDICINAL CHEMISTRY, 2004, 11 (13) :1725-1756
[34]   Marine natural products and related compounds in clinical and advanced preclinical trials [J].
Newman, DJ ;
Cragg, GM .
JOURNAL OF NATURAL PRODUCTS, 2004, 67 (08) :1216-1238
[35]   Advanced preclinical and clinical trials of natural products and related compounds from marine sources [J].
Newman, DJ ;
Cragg, GM .
CURRENT MEDICINAL CHEMISTRY, 2004, 11 (13) :1693-1713
[36]   Scientists are searching the seas for cancer drugs [J].
O'Hanlon, LH .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (10) :662-663
[37]   Phase II trial of dolastatin-10 in patients with advanced breast cancer [J].
Perez, EA ;
Hillman, DW ;
Fishkin, PA ;
Krook, JE ;
Tan, WW ;
Kuriakose, PA ;
Alberts, SR ;
Dakhil, SR .
INVESTIGATIONAL NEW DRUGS, 2005, 23 (03) :257-261
[38]   Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks [J].
Pommier, Y ;
Sordet, O ;
Antony, S ;
Hayward, RL ;
Kohn, KW .
ONCOGENE, 2004, 23 (16) :2934-2949
[39]  
PRASAD SC, 1988, BIOCHEM BIOPH RES CO, V249, P332
[40]   Mitochondria, the killer organelles and their weapons [J].
Ravagnan, L ;
Roumier, T ;
Kroemer, G .
JOURNAL OF CELLULAR PHYSIOLOGY, 2002, 192 (02) :131-137